- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- tipifarnib, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 707
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- RRx-001, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma
- Interventions
- Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy
- Drug · Other · Radiation
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Medulloblastoma, Pontine Glioma, Ependymoma, Astrocytoma, PNET
- Interventions
- Temozolomide, ABT-888
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Primary Glioblastoma Multiforme
- Interventions
- Gliadel Wafer, Temodar and Radiotherapy
- Other
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Brentuximab vedotin
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia
- Conditions
- Lung Cancer
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Waukesha, Wisconsin
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
- Interventions
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 745 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Bleomycin, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Fullerton, California • Palo Alto, California • Chicago, Illinois + 3 more
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Lung Cancer Stage IV, Large Cell Neuroendocrine Carcinoma, Neuroendocrine Tumors, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
- Interventions
- Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma
- Interventions
- rituximab, methotrexate, temozolomide 100 mg/m^2, temozolomide 150 mg/m^2, temozolomide 200 mg/m^2, radiation therapy, post-radiation therapy temozolomide
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 26
- States / cities
- Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more
- Conditions
- Glioblastoma
- Interventions
- Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Advanced Solid Tumours, Small Cell Lung Cancer
- Interventions
- IMP4297(senaparib)
- Drug
- Lead sponsor
- Impact Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Evergreen Park, Illinois • Canton, Ohio • Columbus, Ohio + 1 more
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- Up to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- Avastin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ankylosing Spondylitis, Axial Spondyloarthritis
- Interventions
- Indomethacin, Diclofenac, Meloxicam, Celecoxib
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
- Interventions
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Childhood Solid Tumors
- Interventions
- Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- arsenic trioxide, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Naperville, Illinois
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- temsirolimus, temozolomide, irinotecan hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- San Diego Pacific Oncology & Hematology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Melanoma Metastatic
- Interventions
- Dacarbazine, Carmustine, Neulasta
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona